主要目的：在健康男性与女性受试者中于空腹条件下，评价受试制剂苯溴马隆片（规格：50 mg，生产商：浙江华海制药科技有限公司）和トーアエイヨー株式会社为持证商的参比制剂苯溴马隆片（Urinorm，规格：50 mg）的生物等效性。次要目的：观察受试制剂苯溴马隆片与参比制剂苯溴马隆片（Urinorm）在健康受试者中的安全性。

[Translation]

Primary objective: To evaluate the bioequivalence of the test preparation benzbromarone tablets (specification: 50 mg, manufacturer: Zhejiang Huahai Pharmaceutical Technology Co., Ltd.) and the reference preparation benzbromarone tablets (Urinorm, specification: 50 mg) of which Toaieyo Co., Ltd. is the licensee in healthy male and female subjects under fasting conditions. Secondary objective: To observe the safety of the test preparation benzbromarone tablets and the reference preparation benzbromarone tablets (Urinorm) in healthy subjects.

Start Date23 Mar 2025

Sponsor / Collaborator

Zhejiang Huahai Pharmaceutical Technology Co., Ltd.

CTR20244140

/ CompletedNot Applicable

苯溴马隆片（50 mg）空腹/餐后状态下在健康受试者中的生物等效性试验

[Translation] Bioequivalence study of benzbromarone tablets (50 mg) in healthy volunteers under fasting and fed conditions

主要目的：在健康男性与女性受试者中于空腹/餐后条件下，评价受试制剂苯溴马隆片（规格：50 mg，生产商：浙江华海制药科技有限公司）和トーアエイヨー株式会社为持证商的参比制剂苯溴马隆片（Urinorm，规格：50 mg）的生物等效性。次要目的：观察受试制剂苯溴马隆片与参比制剂苯溴马隆片（Urinorm）在健康受试者中的安全性。

[Translation]

Primary objective: To evaluate the bioequivalence of the test preparation benzbromarone tablets (specification: 50 mg, manufacturer: Zhejiang Huahai Pharmaceutical Technology Co., Ltd.) and the reference preparation benzbromarone tablets (Urinorm, specification: 50 mg) of which Toaieyo Co., Ltd. is the licensee in healthy male and female subjects under fasting/postprandial conditions. Secondary objective: To observe the safety of the test preparation benzbromarone tablets and the reference preparation benzbromarone tablets (Urinorm) in healthy subjects.

Start Date30 Nov 2024

Sponsor / Collaborator

Zhejiang Huahai Pharmaceutical Technology Co., Ltd.

CTR20243754

/ CompletedNot Applicable

苯溴马隆片人体生物等效性试验

[Translation] Bioequivalence study of benzbromarone tablets in human body

采用单中心、随机、开放、两周期交叉、单剂量给药设计比较空腹和餐后给药条件下，浙江金必康医药科技有限公司提供的苯溴马隆片（规格：50 mg）与トーアエイヨー株式会社持证的苯溴马隆片（商品名：Urinorm®，规格：50 mg）在中国健康人群中吸收程度和吸收速度的差异，并评价浙江金必康医药科技有限公司提供的苯溴马隆片（规格：50 mg）的安全性。

[Translation]

A single-center, randomized, open, two-period crossover, single-dose design was used to compare the differences in absorption extent and absorption rate between benzbromarone tablets (specification: 50 mg) provided by Zhejiang Jinbikang Pharmaceutical Technology Co., Ltd. and benzbromarone tablets (trade name: Urinorm®, specification: 50 mg) certified by Toaieyo Co., Ltd. in healthy Chinese people under fasting and postprandial administration conditions, and to evaluate the safety of benzbromarone tablets (specification: 50 mg) provided by Zhejiang Jinbikang Pharmaceutical Technology Co., Ltd.

Start Date05 Nov 2024

Sponsor / Collaborator

Zhejiang Jinbikang Pharmaceutical Technology Co., Ltd

100 Clinical Results associated with Benzbromarone

100 Translational Medicine associated with Benzbromarone

100 Patents (Medical) associated with Benzbromarone

1,254

Literatures (Medical) associated with Benzbromarone

01 Sep 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Development of a fluorescence-based assay for screening of urate transporter 1 inhibitors (II): Optimization of fluorescent substrates and structure-activity relationships analysis

Article

Author: Li, Jing ; Chen, Hongming ; Cai, Haojie ; Lu, Xiaodan ; Dai, Zhixi ; Zhang, Lei

Urate transporter 1 (URAT1) inhibitors represent a promising therapeutic approach for hyperuricemia and gout. A non-radioactive cell-based platform for screening URAT1 inhibitors using 6-carboxyfluorescein (6-CFL) was previously established by our team. In this study, aiming to optimize our testing platform, 10 potential fluorescent substrates were screened from the commercially available fluoresceins using molecular docking and pKa prediction. Among them, dibromofluorescein (DBF) and diiodofluorescein (DIF) were identified as specific transport substrates for UTAR1 with significant fluorescence changes in cellular uptake. DBF and DIF exhibited Km values similar to that of 6-CFL. Using DBF or DIF as substrates, the IC₅₀ values of the URAT1 inhibitors benzbromarone and lesinurad remained within the same order of magnitude as those obtained by 6-CFL. Notably, DBF enables visual detection, further extending the utility of this non-radioactive platform for in vitro screening of URAT1 inhibitors. Molecular dynamics (MD) simulations and free energy calculations were employed to compare the interactions and binding affinities of 6-CFL, DBF, and DIF with URAT1, respectively. Finally, structure-activity relationships (SARs) analysis was conducted to preliminarily identify substituents modulating the binding affinity of commercially available fluoresceins.

01 Apr 2025·LIFE SCIENCES

Benzbromarone improves blood hypercoagulability after TBI by reducing phosphatidylserine externalization through inhibition of TMEM16F expression

Article

Author: Yang, Guili ; Chen, Xin ; Gao, Yalong ; Zhang, Shu ; Li, Lei ; Wang, Cong ; Peng, Ruilong ; Li, Tuo ; Zhang, Jianning ; Li, Kaiji ; Wang, Jinchao

AIMS:

Traumatic brain injury-induced coagulopathy (TBI-IC) frequently occurs after TBI, exacerbating the severity of TBI and affecting patient prognosis. Benzbromarone (BBR) is commonly used to treat hyperuricemia; however, its protective effects against TBI-IC remain unknown. Therefore, we explored whether BBR could improve TBI.

MATERIALS AND METHODS:

C57BL/6 wild-type mice were subjected to fluid percussion injury to mimic TBI, and BBR was administered intraperitoneally 30 min after TBI. Magnetic resonance imaging (MRI) and Evans blue dye extravasation were used to assess the prognosis, tail bleeding time, ELISA, and coagulation tests assess coagulation function. We further explored the potential mechanism by which BBR alleviates hypercoagulation after TBI using flow cytometry.

KEY FINDINGS:

The intraperitoneally injected BBR group showed improved survival and neurological severity scores compared to the TBI group. Subsequently, we found that hypercoagulability developed 3 h after TBI and that the administration of BBR improved this hypercoagulability. BBR also reduced the degree of platelet phosphatidylserine (PS) exposure after TBI, platelet activation, and Ca2+ overload, in addition to inhibition of scramblase activity in procoagulant platelets.

SIGNIFICANCE:

Our findings indicate that BBR reduces PS externalization by inhibiting TMEM16F expression, thereby improving blood hypercoagulability after TBI.

01 Mar 2025·JOINT BONE SPINE

Optimizing gout treatment: A comprehensive review of current and emerging uricosurics

Review

Author: Chaiyakunapruk, Nathorn ; Kaufmann, Dan ; Schlesinger, Naomi

Gout is the most common inflammatory arthritis, affecting approximately 5.1% of adults in the United States (US) population. Gout is a metabolic and autoinflammatory disease. Elevated uric acid pools lead to the precipitation of monosodium urate (MSU) crystals in and around joints, as well as other tissues, and the subsequent autoinflammatory response. Since elevated serum urate (SU) levels (hyperuricemia) correspond with gout severity, urate-lowering therapies (ULTs) are the cornerstone of gout treatment. ULTs include xanthine oxidoreductase inhibitors, uricosurics, less commonly used in the US but widely used in Europe and Asia, including benzbromarone, dotinurad, and probenecid (the only US Food and Drug Administration (FDA) approved uricosuric in the US), and uricases, including rasburicase and pegloticase (available only in the US). Over 90% of the daily load of uric acid filtered by the kidneys is reabsorbed through renal transporters. These urate transporters include uric acid transporter 1 (URAT1), glucose transporter 9, and organic anion transporters 1, 3, and 4 (OAT1, OAT3, OAT4). They are the target of approved and in-the-pipeline uricosurics. Any drug that increases renal excretion of uric acid, independently of the mechanism through which it exerts its effect, may be considered a uricosuric drug. This review discusses drugs that increase renal excretion of uric acid, either approved or in development, as well as off-label drugs with uricosuric properties.

News (Medical) associated with Benzbromarone

03 Dec 2024

·www.businesswire.com

Atom Therapeutics and China Medical System Holdings Enter Exclusive Commercialization Agreement for Lingdolinurad (ABP-671) to Treat Chronic Gout and Hyperuricemia

ZHEJIANG, China--( BUSINESS WIRE )--Atom Therapeutics Co. Ltd (Atom Therapeutics), a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, announced today the company entered into an exclusive commercialization collaboration agreement with a subsidiary of China Medical System Holdings Ltd (CMS) for lingdolinurad (ABP-671), a novel oral small molecule URAT1 inhibitor for the treatment of chronic gout and hyperuricemia, in mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region. Atom Therapeutics and CMS will execute a Contract Sales Organization (CSO) business model. Under the agreement, Atom Therapeutics will receive a substantial sum from CMS through upfront and milestone payments, and will pay marketing and sales service fees to CMS. Lingdolinurad is expected to generate substantial income and revenue from the sales collaborated with CMS. This event marks a significant advancement for Atom Therapeutics in the commercialization of ABP-671. Atom Therapeutics is currently conducting multi-center Phase 2b/3 clinical trials of lingdolinurad worldwide, including in China and the United States. Lingolinurad reduces renal re-absorption of uric acid by inhibiting URAT1 (urate anion transporter 1). Results from multiple clinical trials have demonstrated that lingdolinurad is safe and effective at multiple dose levels (from 1 mg to 12 mg). The 2 mg once-daily tablet is expected to be as effective as benzbromarone (80 mg) and febuxostat (80 mg). The efficacy of lingdolinurad is maintained for over 24 hours without significant safety concerns, positioning it as a potentially safer and more effective treatment option for patients with chronic gout and hyperuricemia. CMS is a platform company linking pharmaceutical innovation and commercialization with a strong product lifecycle management capability, outstanding market promotion capabilities, and extensive commercialization experience. Through this collaboration, Atom Therapeutics will leverage the broad market channels and rich commercialization experience of CMS to achieve rapid promotion and broad clinical application of ABP-671 following its launch. Atom Therapeutics CEO, Chairman and Founder William Dongfang Shi, Ph.D., commented, “This collaboration represents a deep integration of our two companies' business operations and strategic initiatives. We look forward to advancing the implementation and application of ABP-671 through this partnership, delivering more effective treatment options for patients with gout and hyperuricemia as soon as possible.” About Atom Therapeutics Atom Therapeutics Co., Ltd (originally named Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd) officially changed its name on October 8, 2024. Atom Therapeutics is a fast-growing innovative drug company focused on development of best-in-class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company’s lead product, lingdolinurad, is in late-stage clinical development for treatment of chronic gout. Another small molecule ABP-745, for anti-inflammatory and autoimmune conditions, has completed Phase 1 clinical trials in the US and demonstrated good pharmacokinetics and safety, and will enter Phase 2 clinical trials soon. For more information, please visit: https://www.atombp.com or atombp.us . About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class and best-in-class innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group. For more information, please visit: https:/veb.cms.net.cn.

Phase 1License out/inClinical Result

16 Oct 2023

·www.biospace.com

Atom Bioscience Raises $83M in a D-Round Financing to Support Global Pivotal Clinical Trials of ABP-671, a New Treatment for Chronic Gout

JIANGSU, China--(BUSINESS WIRE)-- Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, announced today completion of a D-round financing of approximately $83 million (CNY 600 million) for completion of global pivotal clinical trials of ABP-671, its unique orally administered URAT1 inhibitor for chronic gout. The funds also will be used to advance to clinical stage the company’s innovative pipeline of drugs for inflammatory and metabolic diseases. This round of financing includes new and existing investors and was led by Kaitai Capital. Other investors include Fortune Capital, Huajin Investment, Unifortune and NNFE Investment. After this round of financing, Atom has raised a total of nearly $165 million. "We appreciate the support of every investment institution involved in the D-round financing and previous investors,” said Dr. William Dongfang Shi, CEO, Chairman and Founder of Atom Bioscience. “We are honored to have their trust as we strive to promote innovative best-in-class drugs benefiting gout patients worldwide.” Chronic gout is caused by long-term hyperuricemia (serum uric acid (sUA) > 7 mg/dL or 420 μmol/L). More than 50 million patients suffer from gout worldwide and nearly 10 million in the U.S. Globally, there are more than 200 million people with hyperuricemia. Aside from the acute painful flare-ups associated with gout, the disease seriously affects people's quality of life and can increase the probability of sudden cardiac death and kidney function injury. The performance of existing gout drugs is far from meeting clinical needs. The drugs have poor efficacy and pose serious safety issues, such as leading to kidney failure, sudden cardiac death, or severe liver toxicity. ABP-671 reduces sUA levels by inhibiting renal urate transporter 1 (URAT1), resulting in normal excretion of urate in urine. Its clinical primary endpoint is to reduce sUA to < 6 mg/dL (360 μmol/L) and in previous clinical trials ABP-671 has demonstrated good efficacy, safety and tolerability. In two Phase 2 clinical trials of ABP-671 at doses ranging from 1 mg to 12 mg once a day, ABP-671 at a dose of 1 mg had showed a substantial reduction of sUA. At doses of 6 mg and 8 mg, 100% of subjects achieved the primary clinical end point of < 6 mg/dL. Notably, 100% of subjects experienced sUA levels of < 5 mg/dL (300 μmol/L), and there were 57% and 87.5% of subjects with sUA levels < 4 mg/dL (240 μmol/L), respectively. Some subjects had sUA levels < 3 mg/dL (180 μmol/L). At a dose of 12 mg of ABP-671, 100% of the subjects achieved sUA levels < 4 mg/dL. The two studies showed efficacy of ABP-671 can be maintained up to 24 hours with once daily dosing, and there were no significant adverse effects (AEs) compared to the placebo group. Maintaining sUA levels of 5 mg/dL to 4 mg/dL in gout patients is recommended by many national gout treatment guidelines. At these levels gout tophi are re-dissolved, tophi size and quantity are reduced and eventually acute gout attacks are reduced. This is difficult for most market drugs to achieve. “In terms of safety, ABP-671 is well tolerated. Its adverse events of ABP-671 were mostly grade 1 (mild and generally not bothersome), and the incidence is comparable to that of the placebo group,” said Dr. Shi. “No severe adverse events have occurred with ABP-671 at the doses tested.” He also observed, “A Human Mass Balance study, which evaluates how drugs are absorbed, metabolized and excreted, showed that ABP-671 is mostly excreted in its original form and does not produce any similar metabolites seen with benzbromarone (a currently marketed drug for gout treatment) which causes severe liver toxicity.” Dr. Shi added, “All subjects taking ABP-671 had a significant decrease in their sUA levels, therefore, we also plan to investigate ABP-671 for the treatment of refractory gout. In addition, we submitted a Pre-IND application to the U.S. FDA in August for ABP-745, which is used to treat inflammation and acute gout. We expect to submit the IND application in the U.S. and China in November.” About Atom Bioscience Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd.) is a fast-growing innovative drug company, focused on development of best-in-class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company’s lead product, ABP-671, is in clinical development for treatment of chronic gout. Another small molecule ABP-745 has shown significant efficacy and good safety in animal models of anti-inflammation, and is expected to be in Phase 1 clinical trials soon. For more information, please visit: or atombp.us. View source version on businesswire.com: Contacts Business Development Contact: Roy J. Wu, MBA Sr. Vice President, Business Development Atom Bioscience and Pharmaceutical Co., Ltd Email: roy.wu@atombp.com Source: Atom Bioscience View this news release online at:

Clinical ResultPhase 2INDPhase 1

09 Oct 2023

·www.biospace.com

Atom Bioscience Doses First Patient in Phase 2b/3 Clinical Trial of a New Treatment for Chronic Gout

JIANGSU, China--(BUSINESS WIRE)-- Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today the first patient has been dosed in a Phase 2b/3 clinical trial of ABP-671, a novel orally administered URAT1 inhibitor, for the treatment of chronic gout. The multicenter, randomized, double-blind trial will enroll 580 patients worldwide, including the U.S. The results from Part 1 of the study are expected to be available in Q4/2024. Part 1 will evaluate the safety and efficacy of ABP-671 at different doses and regimens. Part 2 of the study will be a confirmatory study for dosing regimens of ABP-671 selected from Part 1. “Gout affects more than 50 million people worldwide and is on the rise in many countries,” said Atom Bioscience CEO, Chairman and Founder Dr. William Dongfang Shi. "The need for a safe and effective treatment has never been greater. We believe our unique, potent, orally-available drug, ABP-671, will be a better treatment option for patients as suggested by currently available safety and efficacy data.” ABP-671 works by reducing the abnormally high levels of serum uric acid (sUA) and increasing excretion of urate through urine. Gout is one of the most common types of inflammatory arthritis. It is caused by long-term hyperuricemia, an excessive concentration of serum uric acid (sUA) greater than 7 mg/dL (420 μmol/L). Gout seriously affects patients’ quality of life and is associated with other serious comorbidities, including kidney function injury, increasing the probability of sudden cardiac death. Existing drugs for treating chronic gout have poor efficacy and pose serious safety issues, such as leading to kidney failure, sudden cardiac death, or severe liver toxicity. In two Phase 2 clinical trials of ABP-671 at doses ranging from 1 mg to 12 mg once a day, ABP-671 at a dose of 1 mg had showed a substantial reduction of sUA. 100% of subjects with levels of sUA achieved the primary endpoint of < 6 mg/dL at doses of 6 mg and 8 mg. Notably, 100% of subjects also experienced sUA levels of < 5 mg/dL, and there were 57% and 87.5% of subjects with sUA levels < 4 mg/dL (240 μmol/L), respectively. Some subjects had sUA levels < 3 mg/dL (180 μmol/L). At a dose 12 mg of ABP-671, 100% of the subjects achieved sUA levels <4 mg/dL. The two studies showed that the efficacy of ABP-671 can be maintained up to 24 hours with once daily dosing, and there were no significant adverse events compared to the placebo group. “In terms of safety, ABP-671 is well tolerated. Its adverse events were mostly grade 1 (mild and generally not bothersome), and the incidence is comparable to that of the placebo group,” said Dr. Shi. “No severe adverse events have occurred with ABP-671 at the dose tested.” Dr. Shi also added, “A Human Mass Balance study, which evaluates how drugs are absorbed, metabolized and excreted, showed that ABP-671 is mostly excreted in its original form and does not produce any of similar metabolites seen with benzbromarone (a currently marketed drug for gout treatment) which causes severe liver toxicity.” Maintaining sUA levels of 5 mg/dL to 4 mg/dL in gout patients is recommended by many national gout treatment guidelines. At these levels gout tophi are re-dissolved, tophi size and quantity are reduced and eventually acute gout attacks are reduced. This is difficult for most market drugs to achieve. About Atom Bioscience Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd.) is a fast-growing innovative drug company, focused on development of best-in-class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company’s lead product, ABP-671, is in clinical development for treatment of chronic gout. Another small molecule ABP-745 has shown significant efficacy and good safety in animal models of anti-inflammation, and is expected to be in phase 1 clinical trials soon. For more information, please visit: or atombp.us. View source version on businesswire.com: Contacts Business Development Contact: Roy J. Wu, MBA Sr. Vice President, Business Development Atom Bioscience and Pharmaceutical Co., Ltd Email: roy.wu@atombp.com Phase 2b/3 clinical trial information: ( ; NCT05818085) Source: Atom Bioscience View this news release online at:

Clinical ResultPhase 2Phase 1

100 Deals associated with Benzbromarone

External Link

KEGG	Wiki	ATC	Drug Bank
D01056	Benzbromarone	M04AB03	DB12319

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyperuricemia	Japan	Pfizer Japan, Inc.	04 Nov 1986
Gout	Japan	TOA Eiyo Ltd.	01 Aug 1978
Hypertension	Japan	TOA Eiyo Ltd.	01 Aug 1978

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EULAR2024	Not Applicable	Chronic tophaceous gout	15	Benzbromarone	wqvutrlkms(kdnsblkbgj) = jatswujlhq leasfpnham (cteklupoqs, 1.2 - 2.9)	Positive	05 Jun 2024
				Febuxostat	wqvutrlkms(kdnsblkbgj) = mgurqlvfjh leasfpnham (cteklupoqs, 1.1 - 3.6)
EULAR2023	Not Applicable	Gout	98	Benzbromarone	hdjhlmjwnm(osmotpqnec) = ybtebmhsbi rvcpcurrkp (kvnhdxxwsg, 1.0) View more	-	31 May 2023
ASN2022	Not Applicable	Hyperuricemia \| Hypertension \| Chronic Kidney Diseases hyperuricemia \| hypertension	96	Febuxostat	gxdfeneiac(vivxficxjn) = uqlqumahuq jehwqqjukd (pnhfjtrbzt, -2.00 to 1.55)	Negative	05 Nov 2022
				Benzbromarone	-
RBR-5wvg53s (ERS2022)	Phase 2	Pulmonary Cystic Fibrosis Adjuvant TMEM16A \| CFTR	9	Benzbromarone 100 mg/day	mnfssgdyxz(ofnyuktnvx) = kykvtcuwba uqrcgmzefs (djarhavkoo, 3 - 9)	Positive	04 Sep 2022
ATS2021	Not Applicable	-	-	Albuterol	vypkvyfqst(iooxxpgvex) = ivnephcawq joltkicgbo (jqdftjxamu, 4.19)	-	03 May 2021
				Benzbromarone	vypkvyfqst(iooxxpgvex) = gdoimluofv joltkicgbo (jqdftjxamu, 7.75)
ESC2017	Not Applicable	Chronic Kidney Diseases	120	Urate lowing therapy (ULT) group	wvuuuwxhsq(wqauxczcii) = yezzrebhyd mrtyxebbge (dlqboedhwp ) View more	-	28 Aug 2017
				Control group	wvuuuwxhsq(wqauxczcii) = unyditjiru mrtyxebbge (dlqboedhwp ) View more
EULAR2010	Not Applicable	Gout PTX3	-	Benzbromarone	shclmoajgf(vakgnmezvu) = bxctklrdpd oomdwngwio (wcyekyfgcr )	Positive	16 Jun 2010
				Allopurinol	shclmoajgf(vakgnmezvu) = zptithnmjz oomdwngwio (wcyekyfgcr )
EULAR2010	Not Applicable	Gout allantoin	-	Benzbromarone (Patients with gout)	zgrgxzadkk(gpttklghpc) = vyluwjfvyp gxcurqmbso (udgiwdpmaa, 3.5) View more	-	16 Jun 2010
				Benzbromarone (Healthy subjects)	zgrgxzadkk(gpttklghpc) = ohsngbpnyx gxcurqmbso (udgiwdpmaa, 2.3) View more
NCT00422318 (Pubmed \| Circ Heart Fail)	Phase 4	Heart Failure	82	Benzbromarone	iknpseggnf(gooxsxxbiv) = toazutpvdp zkfcxqkqmp (pdjdqnwyzj ) View more	-	01 Jan 2010
				Placebo	iknpseggnf(gooxsxxbiv) = ncalbnjvph zkfcxqkqmp (pdjdqnwyzj ) View more
EULAR2007	Not Applicable	Gout Second line	-	Allopurinol 300 mg	nkryeeanyy(abjymjhkhk) = 10% stopped allopurinol because of adverse drug reactions ynbrljmkhv (blzmtjfewl )	-	13 Jun 2007

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis